Inaktiver Wert

Andere Sprachen Qiagen NV Nasdaq

Aktien

Qiagen N : 2024 QIAGEN N.V. Annual General Meeting of Shareholders Presentation	08.05.
Qiagen N : 2023 Annual Report 2023 Annual Financial Report	08.05.
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics	08.05.
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics	07.05.
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics	07.05.
Qiagen N : Q1 2024 Results Investor Introduction	03.05.
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications	02.05.
QIAGEN Announces the Availability of QCI Secondary Analysis	02.05.
Qiagen N : First Quarter 2024 SEC Filing	02.05.
QIAGEN : A decent start to 2024; guidance unchanged	30.04.
Qiagen Seeks Acquisitions	30.04.
Q1 2024 Results Conference Call Presentation: April 30, 2023	30.04.
Qiagen N : QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance	30.04.
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours	29.04.
Q1 2024 Results Press Release: April 29, 2024, 22:05 CET	29.04.
Qiagen: Q1 Earnings Snapshot	29.04.
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance	29.04.
Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024	29.04.
Qiagen N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	29.04.
Qiagen N : Jaarlijkse financiële verslaggeving	26.04.

Keine Ergebnisse zu dieser Suche

QIAGEN : Anständiger Start ins Jahr 2024; Prognose unverändert

Am 30. April 2024 um 15:32 Uhr